Literature DB >> 24947898

Dashboard systems: implementing pharmacometrics from bench to bedside.

Diane R Mould1, Richard N Upton, Jessica Wojciechowski.   

Abstract

In recent years, there has been increasing interest in the development of medical decision-support tools, including dashboard systems. Dashboard systems are software packages that integrate information and calculations about therapeutics from multiple components into a single interface for use in the clinical environment. Given the high cost of medical care, and the increasing need to demonstrate positive clinical outcomes for reimbursement, dashboard systems may become an important tool for improving patient outcome, improving clinical efficiency and containing healthcare costs. Similarly the costs associated with drug development are also rising. The use of model-based drug development (MBDD) has been proposed as a tool to streamline this process, facilitating the selection of appropriate doses and making informed go/no-go decisions. However, complete implementation of MBDD has not always been successful owing to a variety of factors, including the resources required to provide timely modeling and simulation updates. The application of dashboard systems in drug development reduces the resource requirement and may expedite updating models as new data are collected, allowing modeling results to be available in a timely fashion. In this paper, we present some background information on dashboard systems and propose the use of these systems both in the clinic and during drug development.

Entities:  

Mesh:

Year:  2014        PMID: 24947898      PMCID: PMC4147040          DOI: 10.1208/s12248-014-9632-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  42 in total

Review 1.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

Review 2.  Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.

Authors:  Issam Zineh; Shiew-Mei Huang
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

3.  Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

Authors:  Jeffrey D Wetherington; Marc Pfister; Christopher Banfield; Julie A Stone; Rajesh Krishna; Sandy Allerheiligen; Dennis M Grasela
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

4.  Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.

Authors:  Julie A Stone; Christopher Banfield; Marc Pfister; Stacey Tannenbaum; Sandy Allerheiligen; Jeffrey D Wetherington; Rajesh Krishna; Dennis M Grasela
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

5.  Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs.

Authors:  Mitali Mohan; Kevin T Batty; Jennifer A Cooper; Richard E Wojnar-Horton; Kenneth F Ilett
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

6.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

7.  Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Authors:  Susanna M Proudman; Helen I Keen; Lisa K Stamp; Anita T Y Lee; Fiona Goldblatt; Oliver C Ayres; Maureen Rischmueller; Michael J James; Catherine L Hill; Gillian E Caughey; Leslie G Cleland
Journal:  Semin Arthritis Rheum       Date:  2007-03-27       Impact factor: 5.532

8.  Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.

Authors:  Andrea Tobler; Stefan Mühlebach
Journal:  Int J Clin Pharm       Date:  2013-06-29

9.  Benefits, challenges and obstacles of adaptive clinical trial designs.

Authors:  Shein-Chung Chow; Ralph Corey
Journal:  Orphanet J Rare Dis       Date:  2011-11-30       Impact factor: 4.123

10.  Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy.

Authors:  Jeffrey S Barrett; John T Mondick; Mahesh Narayan; Kalpana Vijayakumar; Sundararajan Vijayakumar
Journal:  BMC Med Inform Decis Mak       Date:  2008-01-28       Impact factor: 2.796

View more
  14 in total

1.  Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.

Authors:  Jessica Wojciechowski; Richard N Upton; Diane R Mould; Michael D Wiese; David J R Foster
Journal:  AAPS J       Date:  2017-04-25       Impact factor: 4.009

2.  Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.

Authors:  Marla C Dubinsky; Becky L Phan; Namita Singh; Shervin Rabizadeh; Diane R Mould
Journal:  AAPS J       Date:  2016-10-13       Impact factor: 4.009

Review 3.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

4.  Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.

Authors:  Laura E Bauman; Ye Xiong; Tomoyuki Mizuno; Philip Minar; Tsuyoshi Fukuda; Min Dong; Michael J Rosen; Alexander A Vinks
Journal:  Inflamm Bowel Dis       Date:  2020-02-11       Impact factor: 5.325

Review 5.  Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis.

Authors:  M J Rosen; P Minar; A A Vinks
Journal:  Aliment Pharmacol Ther       Date:  2015-03-23       Impact factor: 8.171

6.  A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Authors:  Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.

Authors:  Tian Yu; Elena Y Enioutina; Hermine I Brunner; Alexander A Vinks; Catherine M Sherwin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

8.  Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.

Authors:  C Stockmann; J S Barrett; J K Roberts; Cmt Sherwin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-13

Review 9.  Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children.

Authors:  Stephen J Balevic; Michael Cohen-Wolkowiez
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 2.860

Review 10.  Personalized Drug Dosage - Closing the Loop.

Authors:  Geoffrey T Tucker
Journal:  Pharm Res       Date:  2016-12-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.